Review Open Access
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Jun 25, 2023; 12(3): 151-171
Published online Jun 25, 2023. doi: 10.5501/wjv.v12.i3.151
Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation
A H M Nurun Nabi, Hossain Uddin Shekhar, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh
Akio Ebihara, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan
ORCID number: A H M Nurun Nabi (0000-0002-0504-6556); Akio Ebihara (0000-0002-1763-9084); Hossain Uddin Shekhar (0000-0002-8960-0840).
Author contributions: Nabi AHMN designed, reviewed literature, interpreted the data and prepared the first draft of the manuscript, Ebihara A interpreted the data and revised the manuscript, Shekhar HU conceived the idea and prepared the first draft of the manuscript.
Conflict-of-interest statement: Authors declare that there is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Hossain Uddin Shekhar, PhD, Professor, Department of Biochemistry and Molecular Biology, University of Dhaka, Curzon Hall Street, Dhaka 1000, Bangladesh.
Received: December 28, 2022
Peer-review started: December 28, 2022
First decision: January 31, 2023
Revised: February 24, 2023
Accepted: April 13, 2023
Article in press: May 4, 2023
Published online: June 25, 2023


The coronavirus disease 2019 (COVID-19) pandemic caused by the novel beta coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) crippled the whole world and has resulted in large number of morbidity and mortality. The origin of the SARS-CoV-2 is still disputed. The risk of infection with SARS-CoV-2 is dependent on several risk factors as observed in many studies. The severity of the disease depends on many factors including the viral strain, host immunogenetics, environmental factors, host genetics, host nutritional status and presence of comorbidities like hypertension, diabetes, Chronic Obstructive Pulmonary Disease, cardiovascular disease, renal impairment. Diabetes is a metabolic disorder mainly characterized by hyperglycemia. Diabetic individuals are intrinsically prone to infections. SARS-CoV-2 infection in patients with diabetes result in β-cell damage and cytokine storm. Damage to the cells impairs the equilibrium of glucose, leading to hyperglycemia. The ensuing cytokine storm causes insulin resistance, especially in the muscles and liver, which also causes a hyperglycemic state. All of these increase the severity of COVID-19. Genetics also play pivotal role in disease pathogenesis. This review article focuses from the probable sources of coronaviruses and SARS-CoV-2 to its impacts on individuals with diabetes and host genetics in pre- and post-pandemic era.

Key Words: Coronavirus, SARS-CoV-2, Diabetes, MERS, SARS, Single nucleotide polymorphism

Core Tip: The coronavirus disease 2019 (COVID-19) pandemic caused by the novel beta coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) crippled the whole world and has resulted in large number of morbidity and mortality. The origin of the SARS-CoV-2 is still disputed. The risk of infection with SARS-CoV-2 is dependent on several risk factors as observed in many studies. The severity of the disease depends on many factors including the viral strain, host immunogenetics, environmental factors, host genetics, host nutritional status and presence of comorbidities like hypertension, diabetes, Chronic Obstructive Pulmonary Disease, cardiovascular disease, renal impairment. Diabetes is a metabolic disorder mainly characterized by hyperglycemia. Diabetic individuals are intrinsically prone to infections. SARS-CoV-2 infection in patients with diabetes result in β-cell damage and cytokine storm. Damage to the cells impairs the equilibrium of glucose, leading to hyperglycemia. The ensuing cytokine storm causes insulin resistance, especially in the muscles and liver, which also causes a hyperglycemic state. All of these increase the severity of COVID-19. Genetics also play pivotal role in disease pathogenesis. This review article focuses from the probable sources of coronaviruses and SARS-CoV-2 to its impacts on individuals with diabetes and host genetics in pre- and post-pandemic era.


The term “diabetes” first appeared in a medical text book around 1425 and was first suggested by a Greek scientist, Araetus of Cappodocia (81-133AD)[1]. Thomas Willis added the word "mellitus" (meaning "sweet taste of urine") to the word diabetes in 1675. Diabetes was referred to as Madhumeha in ancient Indian medicine[1,2]. In 1776, a British physician named Matthew Dobson identified excess sugar in urine and blood as the cause of their sweet taste, and glucose was identified as the responsible sugar[1,2]. The experimental creation of diabetes in 1889 in experimentally pancreatectomized dogs eventually confirmed that the pancreas is the causative organ of the disease followed by the isolation of insulin in 1922, which finally established that diabetes is an endocrine disorder due to deficiency of insulin[2-4].

Diabetes mellitus has been recognized as one of the major health concerns and is considered a global epidemic affecting 382 million people worldwide. According to the prediction of the World Health Organization, diabetes will be the seventh leading cause of death by 2030[5]. Diabetes is a metabolic disorder caused by hyperglycemia and characterized by polyuria, polyphagia, polydipsia, and weight loss. Diabetes mellitus causes macrovascular and microvascular complications. Macrovascular complications include coronary heart disease, cardiomyopathy, arrhythmias and sudden death, cerebrovascular disease and peripheral artery disease. Myocardial infarction, stroke, and peripheral artery disease are more prevalent in individuals with diabetes mellitus. Microvascular complications include retinopathy, nephropathy, and neuropathy. These complications are the major contributing factors to the increasing mortality rate in patients with diabetes and an estimated 4 million individuals are dying each year due to diabetes related complications.

American Diabetes Association classified diabetes into four categories: Type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and diabetes induced by or related to particular specific illnesses, pathologies, and/or syndromes are the four primary forms or categories of diabetes, respectively. T1DM, often referred to as type 1A diabetes mellitus (DM), insulin-dependent diabetes mellitus (IDDM), or juvenile-onset diabetes, accounts for around 5%-10% of all diabetes cases. It is an autoimmune condition marked by the T-cell-mediated apoptosis of pancreatic beta-cells, which causes an insulin shortage and ultimately leads to hyperglycemia. T2DM, also known as non-insulin-dependent diabetes mellitus accounts for 90%-95% of all cases of diabetes. This kind of diabetes is characterized by two main insulin-related abnormalities: Insulin resistance and β-cell dysfunction. Any degree of glucose intolerance or diabetes, typically discovered in the second or third trimester of pregnancy, is referred to as GDM. Other than T1DM, T2DM, and GDM, other types of diabetes although in smaller percentages relative to the overall diabetic incidence scenario, has been found to be linked to a number of other illnesses, including several pathologies[6].

Endocrinopathies, exocrine pancreatic diseases, diabetes caused by monogenic deficiencies in β-cell function, and diabetes caused by genetic abnormalities in insulin action are the most common types of diabetes. Type 1 diabetes is a chronic autoimmune disease that has both hereditary and environmental causes. In those who have a genetic predisposition to developing autoimmunity, viruses may affect the susceptibility of the infectious disease and trigger it. The most frequently studied viruses in relation to type 1 diabetes are enteroviruses. Pancreatic islet autoimmunity and the onset of type 1 diabetes clinical symptoms have also been linked to respiratory viral infections. In animal models, the influenza virus can infect human pancreatic cell lines and result in pancreatitis and hyperglycemia. In case-report studies, influenza A virus infection has also been linked to acute pancreatitis and type 1 diabetes. There may be a connection between pandemic influenza and type 1 diabetes, according to two small retrospective investigations. These revealed a parallel rise in type 1 diabetes among kids throughout the pandemic influenza timeframe. It normally takes several years from the induction of islet autoimmunity to the clinical presentation of type 1 diabetes, hence studies with longer follow-up following influenza are necessary to clarify how pandemic influenza contributes to the development of diabetes.

Diabetes patients are up to six times more likely than healthy people to require hospitalization for influenza virus or flu-like infections, and they are also more likely to experience infection related complications. Diabetic individuals, especially those with uncontrolled diabetes, are more prone to fungal infections[7]. Community-based pneumonia was more frequent in those diagnosed with diabetes mellitus[8]. Increased mortality risk from cardiovascular disease, chronic lower respiratory illnesses, influenza and pneumonia, and kidney disease is linked to baseline diagnosed diabetes[9]. A regulated immune response that leads to more severe and prolonged lung pathology is most likely the cause of the higher disease severity seen in mice with REMS and co morbid type 2 diabetes[10]. According to a systematic analysis of 637 Middle East respiratory syndrome (MERS)-CoV cases, 50% of the patients had both diabetes and hypertension. Obesity was prevalent in 16% of cases, while cardiac problems were present in 30%[11].


There are similarities between many epidemics and industrial revolutions that have occurred throughout history. No other virus, bacteria, or germ has ever produced as many pandemics and as many deaths on Earth in as little time as plagues and flu. Plague is a disease caused by a bacterium called Yersinia pestis, which is mainly transmitted by rats and one type of fly. History shows that the first plague occurred between 165 and 180 AD (also known as the Antonine Plague that brought the Roman Empire to the brink of destruction) and caused the deaths of 500000 people. Plague outbreaks followed in 541-542 AD, 1347-1351 AD, 1665 AD and 1629-1631 AD. At this time, the word “industrial” revolution did not appear in the world. But history tells us that the plague that occurred in 1885 between the first and second industrial revolutions caused the death of more than a million people in China and India alone. During the Second Industrial Revolution in 1889-1890 and 1918-1919, respectively, the Russian flu and the Spanish flu struck, which took the lives of about 60 million people in the world. During the Third Industrial Revolution, Asian flu (1957-1958), Hong Kong flu (1968-1970), and AIDS (still ongoing since 1981) killed over 40 million people. Among these, flu-like diseases are caused by different types of influenza viruses that belong to the same genus but differ in the structure of their genetic material. The genetic material of the influenza, swine flu viruses is formed by ribonucleic acid, or RNA.

Different types of wildlife frequently carry diseases or disease agents that are harmful, and in some cases fatal, to humans. Recent studies have shown that 60% of the infectious diseases that are currently occurring are zoonotic, that is, the bacteria responsible for these diseases spread from animals to humans. Although these bacteria are common in animals, they can also infect humans. Also 70% of infectious diseases originate from wildlife[12].

The study of Corman et al[13] revealed that bats are the natural host of the coronavirus. Even the age of corona virus found in bats is much longer than that of coronavirus found in other animals. This suggests that the virus has overcome the barriers that normally exist to spread from one species to another and has now adopted humans as its home[14]. Bats are also thought to be the source of two other strains HCoV-NL63 and HCoV-HKU1[15]. Every organism has a natural reservoir. The more we disturb nature, the more likely it is to deplete natural resources. As a result, the microbes are in crisis of existence and to adapt to the changing environment, they cause rapid change or mutation. The significant natural reservoirs of the coronavirus are bats, camels and palm civets. Because of its crown like shape, it is called the "coronavirus". Before making devastating impacts, the human race has always received signs of warnings for larger damage. For example, SARS in 2002-2003, swine flu (2009-2010) in 2009-2010 and MERS, MERS from 2015 to the present.

Coronavirus can be generally divided into four genera - alphacoronavirus, beta coronavirus, gamma and delta. Among these, the beta group is further divided into four groups – A, B, C and D. Human strains of coronaviruses include HCoV 229E (HCoV 229E) and HCoV NL63 of the alpha genus, and HCoV OC43 and HKU1 of the beta genus. Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are also members of the beta genus. A study in 2003 found that the genome of SARS-CoV-1 in humans was 99.8% identical to that of SARS-CoV in palm civets. Later, the genome of human SARS-CoV-1 was found to be approximately 87%-92% similar to that of SARS-CoV recovered from Chinese bats. From this, it is assumed that the natural source of this virus is the Chinese bat. The virus is transmitted to humans using the palm civet as an intermediate vector.

Since the outbreak of MERS-CoV, scientists have begun more research on bat-borne coronaviruses. In line with this, a study in Saudi Arabia found that the genome sequence of human MERS-CoV is nearly 100% identical to a virus found in bats called Taphozous perforates. In addition, some preliminary studies have found viruses similar to this virus in several species of bats. The scientists then sequenced the replication gene of MERS-CoV and found that the virus resembled the HKU4 coronavirus of Tylonycteris bats. However, a 2013 study found that MERS-CoV is actually a member of the beta-coronavirus family and that camels are intermediate carriers of the virus.


The Coronaviruses are enveloped virus. It is a positive sense, single-stranded RNA composed of about 29000 nucleotides. 229E (HCoV-229E) virus is a close relative of the currently prevalent CoV virus in humans due to several conformations. Their habitat was also known to be in the hipposideridae family of African bats. It is hypothesized that they may have used dromedaries as intermediate habitats between bats and humans[16].

The HCoV virus has also been found to be related to viruses in other animals. For example, HCV-OC43 has been shown to be highly homologous to mouse hepatitis virus and bovine respiratory coronavirus[13]. The habitats of these two viruses are rats and cows respectively. An enzyme called hemagglutinin esterase is found in all of them.

Pangolin is also another natural reservoir of coronavirus. Analysis of the Genome Sequence of the currently alarming virus has shown that some parts of the RNA of Novel Coronavirus 2019 or COVID-19 came from bats and some parts came from Pangolin, and this recombination process took place in a third animal. We are destroying these animals for food and medicine.

The genome of SARS-CoV-2 is similar to that of other beta coronaviruses. Most of the proteins that SARS-CoV-2 encodes are similar in length to those that SARS-CoV encodes[17]. From 5′ to 3′, the genomic structure contains leader sequence, ORF1/ab, Spike (S), ORF3a, Envelope (E), Membrane (M), ORF6a, ORF7a, ORF7b, ORF8, Nucleocapsid (N), ORF10 and lacks the hemagglutinin-esterase gene which is found in some β-CoVs. ORF1a/b is made up of 16 non-structural proteins (nsp1–16) and accounts for almost two-thirds of SARS-CoV-2 RNA. The replicase gene encodes a large polyprotein (pp1ab), which is involved in transcription and virus replication. It is fragmented by proteolysis into 16 non-structural proteins. The remaining one-third of the genome, at the 3′-terminus, contains ORFs that code for structural and auxiliary proteins of SARS-CoV-2[18]. With the exception of the S protein, which is different, the structural proteins (E, M, and N) of SARS-CoV-2 share around 90% of their amino acid composition[19,20]. The majority of SARS-CoV-2 non-structural proteins share more than 85% of their amino acid sequences with SARS-CoV[17].


Endemic coronaviruses have animal origins: HCoV-NL63 and HCoV-229E are speculated to have originate in bats whereas; HCoV-OC43 and HKU1 are likely to have originated in rodents[21,22]. Bats are also considered as the natural reservoir of SARS-CoV, MERS-CoV and SARS-CoV-2[16,20,23]. Masked palm civet and dromedary camel are the intermediate hosts of SARS-CoV and MERS-CoV, respectively[23]. However, the intermediate host of SARS-CoV-2 is not clear till date. Pangolin, snakes, minks, turtles, ferret and companion animals are possible candidates for the intermediate hosts of SARS-CoV-2[24] (Figure 1).

Figure 1
Figure 1 Possible intermediate hosts of severe acute respiratory syndrome coronavirus 2. Bat is considered as the natural reservoir of the pandemic-causing beta coronaviruses: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV. The intermediate hosts of SARS-CoV and MERS-CoV are palm civets and dromedary camels, respectively. Although mink, pangolin, ferret and snake have been considered as the intermediate hosts of SARS-CoV-2, however the issue is still unresolved. The figure was created using BioRender (

Cohorts from The United States, Germany, Netherlands, Singapore and the United Kingdom that 20% to 50% individuals not exposed to SARS-CoV-2 previously had T cell activity against peptides that match the sequences of the SARS-CoV-2[25-29]. The T cell activity was mostly due to CD4+ T cells. This might be due to the presence of preexisting memory against endemic coronaviruses which share sequence homology with SARS-CoV-2.


Despite the fact that risks are generally higher in men and rise with age, there is now compelling evidence that those who have a number of medical conditions—including chronic kidney disease, diabetes, lung and liver disease, cardiovascular disease, obesity, immunodeficiency, certain disabilities, and mental health conditions—are also at higher risk[30].

People with complex diabetes, obesity, and psychological disorders are at the highest risk (relative risk of about 1.3 compared to those without these illnesses), whereas those with cardiovascular disease are at a lower risk (relative risk roughly 1.1)[31]. The evidence is inconclusive for asthma, hypertension, and viral hepatitis, while it is scarcer for other illnesses like obesity, sickle cell disease, and substance use disorders. Inflammatory and hormonal routes, as well as social factors like being in a crowded or institutionalized environment, are proposed as possible disease susceptibility and severity processes, albeit the precise mechanisms remain unknown[32,33].

Based on the frequency of chronic diseases, it is projected that one in five people globally are at an increased risk of negative COVID-19 outcomes. Along with age, the risk rises when there are more underlying conditions[34]. Ages 50 to 64 have a fourfold rise in mortality risk compared to those under 40, and 85 and older see a more than tenfold increase[35]. Similar to this, those with one comorbidity or more than 10 comorbidities had a 1.5- and 3.8-times higher risk of dying than those without any underlying diseases[31]. To assist clinical judgments, a number of risk score calculators have been developed using these data[36,37]. Previous research has shown that individuals with H7N9 infection have a 3.4-fold higher chance of having acute respiratory distress syndrome when any comorbidity is present. Similar to the influenza virus, the coronavirus causing SARS-CoV and the MERS-CoV, Covid-19 more easily predisposes susceptible patients to respiratory failure and mortality[38].

A report consisting of 72314 cases in China, case fatality rate was observed to be increase in individuals with preexisting comorbidities like cardiovascular disease (10.5%), diabetes (7.3%), chronic respiratory disease (6.3%), hypertension (6.0%) and cancer (5.6%)[39]. In a study, 399 instances (25.1%) out of the 1590 reported having at least one comorbidity. The prevalence of specific comorbidities included hepatitis B infections (28; 1.8%), chronic obstructive pulmonary disease (24; 1.5%), chronic kidney disease (21; 1.3%), malignancy (18; 1.1%), and immunodeficiency (3; 0.2%). Hypertension (269; 16.9%), other cardiovascular diseases (53.7%), cerebrovascular diseases (30; 1.9%), diabetes (130; 8.2%), and diabetes-related complications were also common. None of the cases had asthma diagnosed by a doctor. In severe instances vs non-severe cases, at least one comorbidity was more frequently observed (32.8% vs 10.3%). Patients with at least one comorbidity tended to be older (mean: 60.8 vs 44.8 years), more likely to experience shortness of breath (41.4% vs 17.8%), nausea, or vomiting (10.4% against 4.3%), and to present abnormally on chest X-rays (29.2% vs 15.1%)[38].


The world has experienced the devastating impact of infectious organism novel coronavirus or SARS-CoV-2 since it's inception in December 2019. Physicians faced enormous challenges to battle against the COVID-19 related complications especially determining or selecting the way of managing the disease i.e., which group of individuals are at higher risk of worst severity[40]. Epidemiological evidences supported that comorbidities have added extra burden to the miseries of pandemic. Among the comorbidities, diabetes took the lead. Further, individuals with diabetes had greater risk of sufferings from the complications caused by this virus. The ongoing COVID-19 pandemic has once again emphasized the importance of preventing and managing type 2 diabetes. Complications even worsen in individuals with both heart disease and diabetes or macrovascular complications due to chronic diabetes.

Diabetic individuals are more prone to both primary and secondary infections caused by bacteria, viruses, fungus and as disease progresses, severity of the disease intensifies compared to their nondiabetic counterparts[10,41]. Obesity and poor control of blood glucose has been found to be directly linked to the clinical outcomes of COVID-19 and poor prognosis followed by increased mortality[42-45]. Zhu et al[45] in a cohort study comprised of 7337 confirmed COVID-19 cases demonstrated that the occurrence of ARDS (16.9% vs 7.2%), acute heart injury (7.3% vs 3.0%), acute kidney injury (3.9% vs 0.8%), septic shock (3.8% vs 1.0%), and DIC (0.5% vs 0.2%) were in individuals with T2D compared to the non-diabetic group. SARS-CoV-2 infects multiorgan system and pancreas is no exception as this organ also expresses angiotensin converting enzyme 2[46]. Previous findings reported presence of angiotensin converting enzyme 2 (ACE2) receptor in the pancreatic beta cells for SARS-CoV-1 virus that acts as the viral entry point leading to the destruction of β-cells and insulin insufficiency causes hyperglycemia[47]. Studies reported morphological, translational and functional modification of pancreas followed by impaired insulin secretion as SARS-CoV-2 is able to successfully infect different cell types of both exocrine and endocrine system which include pancreas[48,49]. SARS-CoV-2 infected patients with poor control of blood sugar had high mortality rate compared to those with well controlled blood glucose. Further investigation revealed that even individuals suffering from COVID-19 disease with a glucose range of 3.9 to 10.0 mmol/L had a lower mortality rate than that of their counterparts with blood glucose levels above 10.0 mmol/L[44]. Moreover, COVID-19 patients with poorly controlled blood glucose had to extend their hospital stay[44]. Thus, better management of blood glucose results in improved outcome in patients with multiple organ damage and reduced the mortality rate in COVID-19 patients[45,50].

In an investigation of two major health-care datasets, US CDC researchers discovered that COVID-19 was associated with a higher risk of diabetes than pre-pandemic acute respiratory infections and that non-SARS-CoV-2 respiratory infections were not. In the post-acute phase of COVID-19, those under the age of 18 who had SARS-CoV-2 infection had a higher probability of being diagnosed with diabetes than non-infected controls. Despite this, the study was unable to differentiate between type 1 and type 2 diabetes[51].

A Scottish study of individuals under the age of 35 found an overall 20% rise in the incidence of type 1 diabetes during the pandemic and an elevated risk of the disease within the first 30 days following SARS-CoV-2 infection, but not afterward[52]. Another study of 428650 individuals with COVID-19 and 428650 matched controls revealed a net increase in the incidence of diabetes in the first four weeks following COVID-19. This increase persisted from five to twelve weeks but not from thirteen to fifty-two weeks. The participants in this study had a median age of 35[53].


Several advances have been made in understanding the pathophysiology of type 2 diabetes. Inflammation plays an important role in the pathogenesis of type 2 diabetes as it mediates hypoxia and cell death of adipose tissue, activation of important factors in signal transduction i.e., nuclear factor-κB (NF-κB) and JUN N-terminal kinase, interleukin-1β and recruitment of immune cells. Factors associated with innate immune response are found to be in the circulation, insulin-sensitive tissues and pancreatic islets in type 2 diabetes. Obesity, one of the major causes of developing insulin resistance followed by type 2 diabetes, leads to elevated levels of C-reactive proteins, haptoglobin, fibrinogen, plasminogen activator inhibitor and serum amyloid A and sialic acid, as well as cytokines and chemokines.

Exaggerated immune response is responsible for the most of the fatalities in case of coronavirus infection. Release of inflammatory cytokines is contributing to the severity of the disease. The inflammatory cytokine release is primary thought to be due to macrophages[54-56]. Infection by the highly pathogenic respiratory viruses such as SARS-CoV-1, Middle East respiratory syndrome (MERS)-CoV, influenza, and respiratory syncytial virus results in the release of substantial amount of cytokine and chemokine by provoking a prolonged inflammatory macrophage phenotype, allowing for direct viral infection of infiltrating cells. This causes massive cell death and damage of alveolar lung tissue, increasing morbidity for the patient[57]. Coronaviruses also induce macrophage mediated cytokine storm in patients with type 2 diabetes[58]. Coronavirus infection causes decrease expression of histone methyltransferase, SETDB2 that results in decrease of the repressive trimethylation of histone 3 Lysine 9 (H3K9me3) at NF-κB binding sites on inflammatory gene promoters of inflammatory genes which in turn effectively increases inflammation[58].

Diabetes is linked to a proinflammatory condition, which may increase the chance of developing severe COVID-19and a higher chance of suffering a cytokine storm. As part of the low-grade chronic inflammation, the proinflammatory cytokines and hazardous metabolites that are present in a cytokine storm are already chronically increased in people with diabetes[59-61]. One of the most significant pathophysiological mechanisms that contribute to higher risk in diabetic patients is believed to involve the proinflammatory NF-kappa-B pathway, which is chronically activated in patients with diabetes[59,62]. Although the underlying pathogenesis of low-grade inflammation leading to a more rapid progression of COVID-19 and the associated cytokine storm is unclear, it is thought to be one of the most important pathophysiological mechanisms. Interleukin-6, interleukin-8, and tumor necrosis factor- may have the worst prognosis or may be fatal for diabetes individuals among the cytokines that have been studied in research. Increased cytokines are linked to risk factors and comorbidities such hypertension and cardiovascular disease and are associated with greater mortality. In diabetic individuals with COVID-19 who had at least one prior comorbidity, especially hypertension and CVD, management of diabetes by insulin treatment may reduce the rate of mortality among diabetic patients, but it may also be contraindicate[63]. The interplay between SARS-CoV-2 infection and diabetes is shown in Figure 2.

Figure 2
Figure 2 Interplay between severe acute respiratory syndrome coronavirus 2 and Diabetes. Severe acute respiratory syndrome coronavirus 2 infection in diabetic individuals result in β-cell damage and cytokine storm. β-cell damage deteriorates the glucose homeostasis resulting in hyperglycemic condition. The resulting cytokine storm causes insulin resistance particularly in liver and muscles which also results in hyperglycemic condition. These altogether deteriorates the condition of the diabetic individual ensuing increased severity of coronavirus disease 2019. The figure was created using BioRender (

Diabetes, an endocrine system disease marked by exceptionally high blood glucose levels, is one of the most common diseases in the world. Vascular problems of both the macrovascular system (cardiovascular disease, or CVD) and the microvascular system are the main causes of morbidity and mortality in patients with diabetes (diabetic kidney disease, diabetic retinopathy, and neuropathy)[64]. Despite the complexity and lack of complete knowledge of the precise mechanisms underlying hyperglycemia-induced vascular damage, increased intracellular glucose are thought to result in increased reactive oxygen species production, altering a number of significant downstream pathways, including the flux of the polyol pathway, the formation and activation of advanced glycation end products, the activation of protein kinase C, and the flux of the hexosamine pathway[65].

The HLA has received the majority of attention. in genetic studies of the diabetes, despite the fact that genome-wide association study (GWAS) have so far identified more than 50 Loci that affect Type I Diabetes (T1D) risk[66-69]. PTPN22 possesses a cluster of unusual variants that disrupt mRNA splicing, according to targeted sequencing of known locus, even though no large-scale sequencing projects have been successfully completed in T1D patients[70]. The largest GWAS on T2D to date is a meta-analysis of 32 European cohorts with roughly 74000 cases and nearly 824000 controls. 243 Loci reached genome-wide significance. Together, these top GWAS signals account for more than 17% of the variation in T2D phenotypes, and 73 signals supporting a single causative variable were discovered by thorough fine-mapping research on these loci[71]. People with polygenic scores in the top 2.5% do have a lower probability of getting the condition, despite the fact that these scores, which combine the genetic risk for T2D across numerous genetic loci, are not any more reliable than clinical markers for T2D prediction[72].

The Diabetic Nephropathy Collaborative Research Initiative, led by the GENIE collaboration, published the largest GWAS on diabetic kidney disease (DKD) to date in 2019[73]. The sample size was increased by three times for European Americans with T1D compared to the prior study, and 16 additional significant genome-wide loci connected to multiple illness definitions were found[73]. The missense variant SNP rs55703767 of the type IV collagen alpha 3 chain gene (COL4A3frequent), whose minor allele (T) guards against DKD and numerous other albuminuria-related symptoms, was the one with the highest correlation. Notably, Alport syndrome is caused by loss-of-function mutations in COL4A3[74]. The mutation was also associated with a reduction in glomerular basement membrane (GBM) thickness in a normoalbuminuric cohort for whom ultrastructural data were available for analysis. The SNP rs55703767 had a significantly greater impact in women. In addition, the protective association in an observational study and in those randomly assigned to a conventional vs intensive glycemic control in the Diabetes Control and Complications Trial was most pronounced in people with higher hemoglobin A1c (HbA1c) levels, which is noteworthy and might be expected for genetic effects expressed in the context of diabetes[73]. In dissected human glomerulus samples from Pima Indians with DKD and glomerulosclerosis, COL4A3 expression levels were discovered to be negatively correlated with GBM surface density. Furthermore, this study project identified three additional genetic loci that exceeded a strict threshold after controlling multiple correction testing (rs144434404 in intron 1 of BMP7, rs142823282 near TAMM41 and rs145681168 in intron 3 of HAND2-AS1)[73]. The SNP rs144434404 in intron 1 of BMP7, a gene involved in renal morphogenesis that is almost exclusively expressed in mouse podocytes, was found to be associated with microalbuminuria. The SNPs rs142823282 and rs145681168, which are located close to TAMM41, as well as rs145681168, which is located in intron 3 of HAND2-AS1, were both substantially linked to microalbuminuria across the entire study. The expression of the neighboring gene PPARG (an expression quantitative trait locus), which is a known T2D GWAS gene but has not been previously studied, was also connected to the TAMM41 signal[74].

With respect to diabetic retinopathy, significant result was found by only one study[75] at the discovery and replication meta-analysis stages by merging two T2D cohorts, one T1D cohort of European ancestry, and one T2D Indian cohort. The genotypes linked to sight-threatening diabetic retinopathy were significantly correlated with genotypes at SNP rs9896052, a variant 17 kb upstream of the GRB2 gene. This gene encodes an epidermal growth factor receptor-binding protein that is expressed in healthy human retina and is elevated in the retina of a transgenic mice model of retinal stress[76]. Since then, there have been two further comprehensive GWAS of diabetic retinopathy, but at the meta-analysis stage, they have not yet been able to provide definitive proof of a genetic relationship. The genome-wide significant intronic variant SNP rs3913535, which affects NOX4, was discovered by the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) discovery cohort.

Regarding diabetic neuropathy, the two main GWAS carried out in the GoDARTS project discovered three signals nominally associated with diabetic nerve pain (rs71647933 in ZSCAN20 in female cases and sex-combined analyses only, rs6986153 at chr8q23 in male cases only, and rs17428041)[77,78]. The presence of foot ulcers in people with diabetic neuropathy was compared to two different groups of control people with diabetes and without foot ulcers in a third GWAS using the same GoDARTS dataset. Comparing cases and controls with diabetic neuropathy, the authors discovered the intronic SNP rs80028505 in MAPK14 related with foot ulcers. These studies are from a single cohort, which is significant.


The COVID-19 is caused by the novel SARS-CoV-2 and was first reported in Wuhan, China. The clinical manifestation of this disease ranges from an asymptomatic to severe disease outcome. Considering the broad spectrum of COVID-19 disease severity, risk factors that predict the disease severity might play a crucial in improving the clinical outcome of COVID-19 patients. Older age, male gender, increased BMI, pre-existing comorbidities and ethnicity are some of the risk factors that are relevant in the context of COVID-19 disease severity and susceptibility. The host genetic predisposition has also been recognized as the crucial risk factor for COVID-19 which is evident by the large number of genome wide association studies, Whole exome sequencing and candidate gene studies conducted by different consortia (COVID-19 Host Genetics Initiative (HGI), Genetics of Mortality In Critical Care (GenOMICC), COVID human genetic effort, independent academic working groups, and commercial genomics service providers such as 23 and Me and Ancestry DNA) regarding the COVID-19 disease to decipher the disease susceptibility and severity[79].

Human Leukocyte Antigen (HLA) are encoded by the most polymorphic MHC genes. Several HLA alleles have been found to be associated with COVID-19 severity and susceptibility. In a study comprising of 82 Chinese individuals, HLA-C*07:29 and B*15:27 were significantly higher in COVID-19 patients compared to control population after correcting the P value[80]. HLA-DRB1*15:01, -DQB1*06:02 and HLA-B*27:07 were significantly higher in 99 severe or critical COVID-19 patients compared to 1017 reference individuals previously analyzed by the research team after applying Bonferroni’s multiple test correction[81]. HLA-DRB1*08 was found to be significantly higher in COVID-19 positive individuals and it was also correlated with mortality[82]. HLA-A*11:01, B*51:01, and C*14:02 alleles were found to be significantly associated with worst COVID-19 outcome[83]. In a study comprising of 619 healthy Sardinian controls and 182 SARS-CoV-2 patients, the haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 was absent in the patients. The HLA allele HLA-C*04:01 allele and the three-loci haplotype HLA-A*30:02, B*14:02, C*08:02 were significantly more frequently in COVID-19 patients[84].

The cytokine storm has been implicated in severe COVID-19. Seven IL-6 (rs140764737, rs142164099, rs2069849, rs142759801, rs190436077, rs148171375, rs13306435) variants and five IL-6R variants (rs2228144, rs2229237, rs2228145, rs28730735, rs143810642) can be implicated in the pathogenesis and severity of COVID-19[85]. Patients with no previous history of severe infection may develop life-threatening COVID-19 pneumonia due to inborn defects of type I IFN immunity that are TLR3- and IRF7-dependent[86]. None of the asymptomatic patients and 2.1% of severely affected males had the TLR7 deleterious variants[87]. Interferon-alpha and -beta receptor subunit 2 (IFNAR2) variant rs2236757 was associated with critical COVID-19[88].

The ACE2 gene is located at position Xp22.2. The S1 subunit of the spike protein (S) of SARS-CoV-2 binds with the ACE2 on the surface of the host cell. The entry into the host cell requires the cleavage at the S1/S2 site by a cellular serine protease, TMPRSS2[89]. The TMPRSS2 variants rs12329760 was found to have deleterious effect on the protease activity and protective role in COVID-19 patients[90]. The T allele of rs2285666 of ACE2 gene was found to be a risk factor for critical COVID-19 especially for men[91]. The splice site variant rs2285666 was also found to be overrepresented in SARS-CoV-2 positive individuals compared to the 100K genome project controls and in hospitalized European patients compared to outpatients. This variant increases the expression of ACE2. The eQTL rs12006793 was found to be more prevalent in patients in this study[92]. The ACE2 variant (rs190509934:C; a rare X-linked variant) was found to reduce the risk of COVID-19 but not the risk according to a meta-analysis[79].

Ellinghaus et al[93] found the 3p21.31 Locus (rs11385942) was associated with severe COVID-19 and respiratory failure in a GWAS study. 3p21.31 spans the gene cluster containing the genes sodium-amino acid transporter 1 (SLC6A20), human leucine zipper transcription factor like 1, CC motif chemokine receptor 9, FYVE and coiled-coil domain-containing protein 1, C-X motif chemokine receptor 6, and X-C motif chemokine receptor 1 genes. A second locus 9q34.2 (rs657152) overlapping with the ABO locus was also found to be significantly associated with severe COVID-19[93]. The GenOMICC (Genetics of Mortality In Critical Care) genome-wide association study involving 2244 critically ill COVID-19 patients from 208 United Kingdom intensive care units, identified significant associations on chromosome 12q24.13 (rs10735079), chromosome 19p13.2 (rs74956615), chromosome (rs2109069) and on chromosome 21q22.1 (rs2236757)[88].

The rs35705950 of the MUC5B was found to be associated with hospitalization in COVID-19. rs35705950 is a promoter specific mutation ( The association of rs1886814 in the transcription factor FOXP4 was found to be associated with hospitalization by HGI[94]. Independent of pre-existing dementia, cardiovascular illness, or type 2 diabetes, the ApoE e4e4 homozygous genotype was observed to increase the risk of severe COVID-19[95].


It has been demonstrated that COVID-19's clinical presentation varies greatly, frequently exhibiting substantial respiratory problems. A number of patients with SARS-CoV-2 have gone on to experience long-term problems from the virus, making it notable. Long-haul COVID-19 has evolved to represent a wide range of problems and sequelae of symptoms that may occur, beyond the original reports of individuals feeling weary for months following initial infection[96]. Lung fibrosis, venous thromboembolism (VTE), arterial thromboses, heart thrombosis and inflammation, stroke, "brain fog," dermatological issues, and general mood dysfunctions are some of the potential late consequences that could result from COVID-19 infection, according to prior investigations[97]. Despite the wide range of these long-term problems, certain patient characteristics have been proven to predict which symptoms they would experience and for how long[98].

COVID-19 is mostly a respiratory disease, despite the fact that SARS-CoV-2 can have widespread effects throughout the body. Following COVID-19 infection, numerous long-term pulmonary problems have been reported. Dyspnea, ventilator dependency, oxygen dependence, pulmonary function test (PFT) abnormalities, and fibrotic lung disease are only a few of them. Dyspnea is the most frequent pulmonary symptom associated with COVID-19, and it might last for two months in 22.9% to 53.3% of patients[99-101]. Infection with SARS-CoV-2 can lead to verifiable long-term alterations in pulmonary physiology in addition to subjective symptoms. Up to 6.6% of survivors who make it to hospital discharge have been found to be oxygen dependent[101]. Long-term weaning from ventilator use is not frequently successful in patients with respiratory insufficiency necessitating a tracheostomy. Only 48% of patients in Spain's 1890 tracheostomy patients were successful in weaning off artificial breathing at the 1-month follow-up[102]. Previous studies have also discussed abnormalities in lung function as determined by PFT. In a study of 55 non-critically ill COVID-19 patients in China, PFT evaluation over a three-month follow-up period indicated abnormalities in 25% of patients, with a decrease in DLCO being the most prevalent (16%)[103]. Salem et al[104] made similar observations with elevated incidence of restrictive lung findings when compared with matched controls.

After being released from the hospital following COVID-19, cardiac problems are a frequent complaint. As many as 21% of patients had chest pain 60 days after leaving the hospital, according to Carfì et al[99]. Palpitations have also been reported to occur often in as many as 9% of patients at the 60-day follow-up. Aside from the subjective cardiac symptoms listed among the long-term effects of SARS-CoV-2 infection, there have also been a number of quantifiable results. Investigation into the precise prevalence of postural tachycardia syndrome, which has been associated with SARS-CoV-2 infection, is still ongoing[105].

Acute COVID-19 has been linked to a higher risk of thrombotic events, particularly in patients who are severely sick[106,107]. The causes of this coagulopathy are multifaceted and include hypoxia's impact on the activation of hypoxia-inducible transcription factors, microvascular dysfunction, and enhanced expression of tissue factors in response to inflammatory cytokines[108,109]. The regular administration of intermediate-dose anticoagulation (enoxaparin 1 mg/kg) is recommended due to the elevated risk of thrombosis found in this patient population. Recently, a comparison of typical preventive anticoagulation (enoxaparin 40 mg daily) and severely ill individuals with a randomized controlled method in the INSPIRATION trial, COVID-19. Treatment with intermediate-dose anticoagulation did not appear to lower the composite endpoint of arterial or venous thrombosis. ECMO, or death at 30 days as compared to prophylactic anticoagulation at a standard dose[110]. Even though bleeding incidents do occur, most patients benefit more from inpatient VTE prevention than they risk due to the minimal risk of significant bleeding[111,112].

With SARS-CoV-2 infection came a number of long-term neurological and behavioral problems. Two months after the acute infection, patients continued to experience neurological symptoms as fatigue, muscle weakness, difficulty sleeping, myalgia, and headaches, according to long-term symptom data from numerous sources[99,113]. These signs and symptoms have come to represent the long COVID syndrome. In contrast to other viral infections, SARS-CoV-2 infection has also been associated with loss of taste and smell. At a 2-month follow-up, 11% to 13.1% of patients still had chronic loss of taste and smell[100,113]. Due to the considerable burden of severe, life-threatening illness and acute respiratory distress syndrome (ARDS) associated with COVID-19, cognitive disturbances comparable to those shown in ARDS patients in previous studies should be anticipated. At one year of follow-up, ARDS survivors from other causes have reported memory problems (13%), verbal fluency problems (16%), and executive function problems (49%)[114].

A review of the literature found that of the reported cutaneous manifestations of COVID-19 infection, the most prevalent cutaneous manifestation was maculopapular exanthem (morbilliform), which was reported by 36.1% of 72 documented patients in 18 studies. Other cutaneous manifestations included papulovesicular rash (34.7%), urticaria (9.7%), painful red acral purple papules (15.3%), and urticaria, with 19.4% of these manifestations[115]. Another international study of 2560 patients reported that the most prevalent cutaneous manifestation (51.5%) was pernio-like lesions, and that children had a 1.5-day latency period between upper-respiratory infections and cutaneous findings compared to adults, who had a 7.9-day latency period[116]. Only 47 of 1655 hospitalized patients in the Chinese post-acute COVID-19 study (3%) reported skin rashes six months after the infection started[113]; hair loss, on the other hand, was a symptom that was much more frequently reported for patients’ months after the COVID-19 infection and was reported in 24 of 120 patients (20.0%) as a post-discharge symptom 110 days after hospital discharge. However, other, more uncommon presentations have been described in case reports, indicating that, although having the same virus in their bodies, the symptoms in various patients may change[117]. Vesicular rashes may be diagnostic of an initial diagnosis of COVID 19 and may be predictive of disease prognosis, although the particular use of these symptoms in this manner has not yet been proven and should be the subject of future prospective research[118].

Children often experience a milder disease during the acute phase of COVID-19 and receive dia-gnoses at a lesser rate than adults[119]. Multisystem inflammatory syndrome in children (MIS-C), which is characterized by fever and multiorgan dysfunction in the weeks following SARS-CoV-2 infection[120,121], is one of the consequences and sequelae of infection. 316 cases per 1000000 infections are reported for MIS-C, which primarily affects youngsters from racial/ethnic minority backgrounds[122,123]. Nearly 75% of MIS-C patients require ICU admission, and the condition shares characteristics with both severe acute COVID-19 and Kawasaki illness[120-122]. The most typical symptoms include gastrointestinal issues, cardiovascular issues, respiratory issues, mucocutaneous issues, and neurological issues[122-124].

Poorer COVID-19 outcomes have been linked to pre-existing diabetic mellitus. Meanwhile, COVID-19 has been linked to both type 1 and type 2 diabetes patients' new-onset hyperglycemia and rapid decompensation of diabetes, including diabetic ketoacidosis[125]. In addition to iatrogenic hyperglycemia caused by steroid usage, other suggested mechanisms for hyperglycemia after infection include insulin resistance brought on by the inflammatory state and insulin secretory deficiencies from defective beta cells—caused either directly or indirectly by viral damage[125,126]. Unknown numbers of people with newly discovered diabetes following COVID-19 may have already had undiagnosed diabetes prior to infection, which was merely concealed or made worse by the infection. It's also not certain whether diabetes that develops after being hospitalized for COVID-19 is a lifelong condition. In order to better understand the relationship between COVID-19 and diabetes and to better define the length of post-COVID-19 diabetes, the global CoviDiab Registry was established[127].

Acute COVID-19 patients frequently experience acute kidney injury (AKI), and 5% of all hospitalized patients need inpatient renal replacement treatment[128]. The causes of AKI are multifactorial, and they include aberrant coagulation, systemic hypoxia, inflammatory cytokine effects, and direct virus harm[129]. The most frequent histological finding is acute tubular necrosis, however glomerulopathy[130] and microvascular thrombi[131] can also occur[132-136]. AKI is linked to an increase in hospital mortality, and those who make it out of the hospital[128].


Frequencies of variations in human ACE2 receptor gene is not uniform rather varied considerably from population to populations. Mutations emerging within the SARS-CoV-2 genome and natural polymorphisms harbored within the ACE2 receptor gene are crucial for the binding of receptor binding domain of spike protein of SARS-CoV-2 followed by the entry and transmission of the virus[137]. Several studies have been conducted to evaluate the binding affinity of the novel SARS-CoV-2 variants to hACE2[138-140] and association of population specific ACE2 variants with disease susceptibility as well as severity has been reported[141-143]. Presence of ACE2 receptor polymorphisms can alter binding interaction with SARS-CoV-2 followed by COVID-19 disease susceptibility[144] on one hand while on the other side different mutations in SARS-CoV-2 revealed varied binding pattern to its host receptor, ACE2[145].

Studies on different population revealed linkage between the single nucleotide polymorphisms within the angiotensin converting enzyme 2 receptor gene and hypertension, diabetes, cardiovascular diseases[146,147]. The ACE2 variants rs2285666, rs879922, rs4646188, rs2106809, rs4240157, rs4830542, rs2158083, rs879922, rs1514283, rs2074192, rs4646155, rs4646176, rs4646174 and rs233575 have been reported to be associated with primary hypertension while rs2106809, rs2074192, rs4646156, rs879922, rs4240157 and rs233575 were found to be linked with left ventricular hypertrophy[148]. Incompatible results have been reported regarding association of ACE2 gene variants with the risk as well as severity of COVID-19 disease. Studies conducted on Turkish, Italian and Spanish populations reported that ACE2 receptor gene rs2106809, and rs2285666 polymorphisms were not associated with the severity of COVID-19 infection[148-151] while ACE2 rs2285666 (AA allele) and ACE2 rs2074192 (TT allele), and for ACE2 rs4646174 (GG allele), ACE2 rs4646156 (TT allele) and ACE2 rs2158083 (TT allele) the most significant correlation with COVID-19 in Polish population[152]. On the other hand, in another study Cafiero et al[153] reported SNPs within the members of renin angiotensin system such as rs2074192 within ACE2, rs1799752 within ACE1 and rs699 within angiotensinogen, SNPs could potentially be a valuable tool for predicting the clinical outcome of SARS-CoV-2 infected patients.

Intronic variant rs228666 (located in intron 3) can cause change in mRNA splicing followed by altered ACE2 expression which ultimately results in higher binding affinity to novel coronavirus[152] and similar characteristics in case of rs2158083 was observed in patients with arterial hypertension[138]. Another intronic variant rs2074192 has been demonstrated to dysregulate SARS-CoV-2 binding to its host receptor by mediating imbalance in ACE2 transcription/translation through inducing changes in secondary structure of RNA[138,152]. Sienko et al[152] demonstrated significant correlation of the ACE2 receptor gene rs2074192, rs2158083, rs2285666, rs4646156, rs4646174 polymorphisms with the severity of COVID-19 in adult patients. Strong correlation of T allele and TT genotype with respect to of rs2074192 within ACE2 receptor gene has been shown with disease severity caused by SARS-CoV-2[151,152] and in French-Canadian and British patients (n = 1644) with COVID-19 disease in obese smoking males[154]. Recent research has demonstrated that persons with type 2 diabetes (T2D) experience COVID-19 with greater severity and mortality as compared to healthy individuals. Patients with T2D who are infected with SARS-CoV-2 are more prone to experience severe cytokine storm consequences and need to be hospitalized to high-dependency or intensive care facilities. Due to the severe activation of inflammatory cascades, some COVID-19 individuals are known to experience different types of acute respiratory distress syndrome and have a greater mortality risk.

Recently, Wu et al[155] tried to find the common genetic determinants between T2D and COVID-19. They analyzed the key pathways that were shared between T2D and COVID-19 in order to identify the common pathways between the two diseases. Using iGSEA4GWAS, they discovered chemokine binding, G-protein coupled chemoattractant receptor activity pathways (CCR2 and CCR3), TFAP2 family pathway (TFAP2B), and ventricular cardiac muscle cells differentiation (RARB and PROX1) pathways shared by T2D and COVID-19. Immunological cell recruitment to infection sites is aided by the chemokine binding pathway, and leukocyte chemotaxis and innate and adaptive host immune responses are mediated by the G-protein coupled chemoattractant receptor. Additionally, using PASCAL, 15 pathways that were common between T2D and COVID-19 were discovered. These pathways were linked to a number of biological functions and organs, including the heart, axons, and calcium channels. However, no shared pathways between the four pathway-based analytic programs were discovered. 394 genes were associated with T2D according to PASCAL analysis, while 58 genes were associated with COVID-19. Five were discovered to be common between T2D and COVID-19 after comparing the important genes in T2D and COVID-19: PTPRD, CSMD1, MAGI1, ASIC2, and DAB1.

Significantly positive genetic correlations between T2D and COVID-19 were found in genome-wide linkage disequilibrium score regression studies (R for genetic = 0.15, P value = 0.01). There is a slight polygenic overlap between COVID-19 and T2D, as evidenced by the enrichment of associations with COVID-19 across different degrees of association with T2D[22]. Wu et al[155] further revealed two loci shared between COVID-19 and T2D: ABO (rs505922, intronic) and NUS1 (rs3924604, intronic) based on a threshold of conjFDR<0.05. Both of these independent loci were displaying a consistent direction when the effect directions of the shared independent loci were compared (conjFDR<0.05). One locus (rs505922) has shown a favorable effect, whilst the other (rs3924604) demonstrated a detrimental effect. SNPnexus was used to identify these two genes from two separate SNPs. In the genes closest to the identified loci shared between COVID-19 and T2D, eight pathways were found to be significantly overrepresented, with the faulty DHDDs causing retinitis pigmentosa 59 pathway being the most significant (P value = 1.88 × 10-4).


The world has overcome the devastating impact of COVID-19 by undergoing massive vaccination program against SARS-CoV-2. The pandemic has also showed us weaknesses of the health care system of both the developed and underdeveloped world. Also, we should think about preserving our forests, water reservoirs i.e., the natural habitats of all living beings. To do so, we need to revisit the actions of climate change. Moreover, the world researchers, policy makers, health care providers should also consider the probable impacts of long COVID on human health. Understanding the genetics of hosts and disease pathophysiology could be one of the many steps towards better human health and well-being.


Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Infectious diseases

Country/Territory of origin: Bangladesh

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Ait Addi R, Morocco; Wang CY, Taiwan S-Editor: Ma YJ L-Editor: A P-Editor: Liu JH

1.  Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002;23:373-378.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Eknoyan G, Nagy J. A history of diabetes mellitus or how a disease of the kidneys evolved into a kidney disease. Adv Chronic Kidney Dis. 2005;12:223-229.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 40]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
3.  Hegele RA, Maltman GM. Insulin's centenary: the birth of an idea. Lancet Diabetes Endocrinol. 2020;8:971-977.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 30]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
4.  King KM, Rubin G. A history of diabetes: from antiquity to discovering insulin. Br J Nurs. 2003;12:1091-1095.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 15]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
5.  World Health Organization  Global status report on noncommunicable diseases 2010. Available from:  [PubMed]  [DOI]  [Cited in This Article: ]
6.  American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81-S90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2986]  [Cited by in F6Publishing: 3132]  [Article Influence: 313.2]  [Reference Citation Analysis (15)]
7.  Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol. 2015;83:401-408.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 68]  [Cited by in F6Publishing: 72]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
8.  Jensen AV, Faurholt-Jepsen D, Egelund GB, Andersen SB, Petersen PT, Benfield T, Witzenrath M, Rohde G, Ravn P; German Community-Acquired Pneumonia Competence Network (CAPNETZ);  German Community-Acquired Pneumonia Competence Network (CAPNETZ). Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65:2091-2098.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 18]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
9.  Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. Diabetes Metab J. 2019;43:319-341.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 114]  [Article Influence: 22.8]  [Reference Citation Analysis (0)]
10.  Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 199]  [Cited by in F6Publishing: 223]  [Article Influence: 44.6]  [Reference Citation Analysis (0)]
11.  Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 459]  [Cited by in F6Publishing: 439]  [Article Influence: 54.9]  [Reference Citation Analysis (0)]
12.  Piret J, Boivin G. Pandemics Throughout History. Front Microbiol. 2020;11:631736.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 104]  [Cited by in F6Publishing: 173]  [Article Influence: 57.7]  [Reference Citation Analysis (0)]
13.  Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human Coronaviruses. Adv Virus Res. 2018;100:163-188.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 557]  [Cited by in F6Publishing: 563]  [Article Influence: 93.8]  [Reference Citation Analysis (0)]
14.  Dhama K, Patel SK, Sharun K, Pathak M, Tiwari R, Yatoo MI, Malik YS, Sah R, Rabaan AA, Panwar PK, Singh KP, Michalak I, Chaicumpa W, Martinez-Pulgarin DF, Bonilla-Aldana DK, Rodriguez-Morales AJ. SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med Infect Dis. 2020;37:101830.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 129]  [Article Influence: 32.3]  [Reference Citation Analysis (0)]
15.  Liu DX, Liang JQ, Fung TS.   Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Encycl Virol 2021; 428.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 169]  [Article Influence: 56.3]  [Reference Citation Analysis (0)]
16.  Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2945]  [Cited by in F6Publishing: 3010]  [Article Influence: 752.5]  [Reference Citation Analysis (0)]
17.  Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-154.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2083]  [Cited by in F6Publishing: 2519]  [Article Influence: 839.7]  [Reference Citation Analysis (0)]
18.  Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics. 2021;113:1221-1232.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 92]  [Article Influence: 30.7]  [Reference Citation Analysis (0)]
19.  Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7915]  [Cited by in F6Publishing: 7185]  [Article Influence: 1796.3]  [Reference Citation Analysis (0)]
20.  Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15248]  [Cited by in F6Publishing: 13141]  [Article Influence: 3285.3]  [Reference Citation Analysis (0)]
21.  Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24:490-502.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1725]  [Cited by in F6Publishing: 1752]  [Article Influence: 219.0]  [Reference Citation Analysis (0)]
22.  Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2017;25:35-48.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 457]  [Cited by in F6Publishing: 460]  [Article Influence: 57.5]  [Reference Citation Analysis (0)]
23.  de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-534.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2157]  [Cited by in F6Publishing: 2158]  [Article Influence: 269.8]  [Reference Citation Analysis (0)]
24.  Zhao J, Cui W, Tian BP. The Potential Intermediate Hosts for SARS-CoV-2. Front Microbiol. 2020;11:580137.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 71]  [Article Influence: 17.8]  [Reference Citation Analysis (0)]
25.  Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, Eschweiler S, Grifoni A, Pelosi E, Weiskopf D, Sette A, Ay F, Seumois G, Ottensmeier CH, Vijayanand P. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell. 2020;183:1340-1353.e16.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 384]  [Cited by in F6Publishing: 345]  [Article Influence: 86.3]  [Reference Citation Analysis (0)]
26.  Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489-1501.e15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2147]  [Cited by in F6Publishing: 2525]  [Article Influence: 631.3]  [Reference Citation Analysis (0)]
27.  Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, van den Akker JPC, Molenkamp R, Koopmans MPG, van Gorp ECM, Haagmans BL, de Swart RL, Sette A, de Vries RD. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 743]  [Cited by in F6Publishing: 667]  [Article Influence: 166.8]  [Reference Citation Analysis (0)]
28.  Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, Dingeldey M, Kruse B, Fauchere F, Baysal E, Mangold M, Henze L, Lauster R, Mall MA, Beyer K, Röhmel J, Voigt S, Schmitz J, Miltenyi S, Demuth I, Müller MA, Hocke A, Witzenrath M, Suttorp N, Kern F, Reimer U, Wenschuh H, Drosten C, Corman VM, Giesecke-Thiel C, Sander LE, Thiel A. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270-274.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 803]  [Cited by in F6Publishing: 861]  [Article Influence: 215.3]  [Reference Citation Analysis (0)]
29.  Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457-462.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1275]  [Cited by in F6Publishing: 1338]  [Article Influence: 334.5]  [Reference Citation Analysis (0)]
30.  Adab P, Haroon S, O'Hara ME, Jordan RE. Comorbidities and covid-19. BMJ. 2022;377:o1431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 38]  [Article Influence: 19.0]  [Reference Citation Analysis (0)]
31.  Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, Gundlapalli AV, Boehmer TK, Blanck HM. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70:355-361.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 178]  [Cited by in F6Publishing: 254]  [Article Influence: 84.7]  [Reference Citation Analysis (0)]
32.  Bigdelou B, Sepand MR, Najafikhoshnoo S, Negrete JAT, Sharaf M, Ho JQ, Sullivan I, Chauhan P, Etter M, Shekarian T, Liang O, Hutter G, Esfandiarpour R, Zanganeh S. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. Front Immunol. 2022;13:890517.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 40]  [Article Influence: 20.0]  [Reference Citation Analysis (0)]
33.  Liu L, Ni SY, Yan W, Lu QD, Zhao YM, Xu YY, Mei H, Shi L, Yuan K, Han Y, Deng JH, Sun YK, Meng SQ, Jiang ZD, Zeng N, Que JY, Zheng YB, Yang BN, Gong YM, Ravindran AV, Kosten T, Wing YK, Tang XD, Yuan JL, Wu P, Shi J, Bao YP, Lu L. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. EClinicalMedicine. 2021;40:101111.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 79]  [Article Influence: 26.3]  [Reference Citation Analysis (0)]
34.  Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C, McKee M, Troeger C, Ong KL, Checchi F, Perel P, Joseph S, Gibbs HP, Banerjee A, Eggo RM; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8:e1003-e1017.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 693]  [Cited by in F6Publishing: 597]  [Article Influence: 149.3]  [Reference Citation Analysis (0)]
35.  Pennington AF, Kompaniyets L, Summers AD, Danielson ML, Goodman AB, Chevinsky JR, Preston LE, Schieber LZ, Namulanda G, Courtney J, Strosnider HM, Boehmer TK, Mac Kenzie WR, Baggs J, Gundlapalli AV. Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19-United States, March-September 2020. Open Forum Infect Dis. 2021;8:ofaa638.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 55]  [Article Influence: 13.8]  [Reference Citation Analysis (0)]
36.  Nafilyan V, Humberstone B, Mehta N, Diamond I, Coupland C, Lorenzi L, Pawelek P, Schofield R, Morgan J, Brown P, Lyons R, Sheikh A, Hippisley-Cox J. An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England. Lancet Digit Health. 2021;3:e425-e433.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 32]  [Article Influence: 10.7]  [Reference Citation Analysis (0)]
37.  Coggon D, Croft P, Cullinan P, Williams A. Assessment of workers' personal vulnerability to covid-19 using 'covid-age'. Occup Med (Lond). 2020;70:461-464.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 30]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
38.  Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11409]  [Cited by in F6Publishing: 10959]  [Article Influence: 2739.8]  [Reference Citation Analysis (0)]
40.  Forde R, Arente L, Ausili D, De Backer K, Due-Christensen M, Epps A, Fitzpatrick A, Grixti M, Groen S, Halkoaho A, Huber C, Iversen MM, Johansson UB, Leippert C, Ozcan S, Parker J, Paiva AC, Sanpetreanu A, Savet MA, Rosana SC, Szewczyk A, Valverde M, Vlachou E, Forbes A; FEND COVID-19 consortium. The impact of the COVID-19 pandemic on people with diabetes and diabetes services: A pan-European survey of diabetes specialist nurses undertaken by the Foundation of European Nurses in Diabetes survey consortium. Diabet Med. 2021;38:e14498.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 33]  [Article Influence: 11.0]  [Reference Citation Analysis (0)]
41.  Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33:1491-1493.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 227]  [Cited by in F6Publishing: 215]  [Article Influence: 15.4]  [Reference Citation Analysis (0)]
42.  Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1653]  [Cited by in F6Publishing: 2072]  [Article Influence: 518.0]  [Reference Citation Analysis (0)]
43.  Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020;71:896-897.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 810]  [Cited by in F6Publishing: 794]  [Article Influence: 198.5]  [Reference Citation Analysis (0)]
44.  Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14:813-821.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 462]  [Cited by in F6Publishing: 426]  [Article Influence: 106.5]  [Reference Citation Analysis (0)]
45.  Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31:1068-1077.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 978]  [Cited by in F6Publishing: 1004]  [Article Influence: 251.0]  [Reference Citation Analysis (0)]
46.  Gupta R, Meena K, Patnaik I, Kumar A. ACE2 Expression in the Pancreas and Association With COVID-19 Infection. Pancreas. 2021;50:e1-e2.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
47.  Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, Kwong RMW, Kumar P, Logan KM. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care. 2020;43:e170-e171.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 214]  [Cited by in F6Publishing: 236]  [Article Influence: 59.0]  [Reference Citation Analysis (0)]
48.  Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, Weil T, Koepke L, Bozzo CP, Read C, Fois G, Eiseler T, Gehrmann J, van Vuuren J, Wessbecher IM, Frick M, Costa IG, Breunig M, Grüner B, Peters L, Schuster M, Liebau S, Seufferlein T, Stenger S, Stenzinger A, MacDonald PE, Kirchhoff F, Sparrer KMJ, Walther P, Lickert H, Barth TFE, Wagner M, Münch J, Heller S, Kleger A. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149-165.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 282]  [Cited by in F6Publishing: 312]  [Article Influence: 104.0]  [Reference Citation Analysis (0)]
49.  Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell. 2020;27:125-136.e7.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 508]  [Cited by in F6Publishing: 466]  [Article Influence: 116.5]  [Reference Citation Analysis (0)]
50.  Gianchandani R, Esfandiari NH, Ang L, Iyengar J, Knotts S, Choksi P, Pop-Busui R. Managing Hyperglycemia in the COVID-19 Inflammatory Storm. Diabetes. 2020;69:2048-2053.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 79]  [Article Influence: 19.8]  [Reference Citation Analysis (0)]
51.  Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, Pavkov ME, Rolka DB, Wiltz JL, Bull-Otterson L, Gray S, Boehmer TK, Gundlapalli AV, Siegel DA, Kompaniyets L, Goodman AB, Mahon BE, Tauxe RV, Remley K, Saydah S. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59-65.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 211]  [Cited by in F6Publishing: 161]  [Article Influence: 80.5]  [Reference Citation Analysis (0)]
52.  McKeigue PM, McGurnaghan S, Blackbourn L, Bath LE, McAllister DA, Caparrotta TM, Wild SH, Wood SN, Stockton D, Colhoun HM. Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland. Diabetes Care. 2022;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 32]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
53.  Rezel-Potts E, Douiri A, Sun X, Chowienczyk PJ, Shah AM, Gulliford MC. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK. PLoS Med. 2022;19:e1004052.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 44]  [Article Influence: 22.0]  [Reference Citation Analysis (0)]
54.  Merad M, Martin JC. Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:448.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 75]  [Cited by in F6Publishing: 85]  [Article Influence: 21.3]  [Reference Citation Analysis (0)]
55.  Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6366]  [Cited by in F6Publishing: 6357]  [Article Influence: 1589.3]  [Reference Citation Analysis (0)]
56.  Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145-159.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 228]  [Cited by in F6Publishing: 239]  [Article Influence: 23.9]  [Reference Citation Analysis (0)]
57.  Sang Y, Miller LC, Blecha F. Macrophage Polarization in Virus-Host Interactions. J Clin Cell Immunol. 2015;6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 52]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
58.  Melvin WJ, Audu CO, Davis FM, Sharma SB, Joshi A, DenDekker A, Wolf S, Barrett E, Mangum K, Zhou X, Bame M, Ruan A, Obi A, Kunkel SL, Moore BB, Gallagher KA. Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. Proc Natl Acad Sci USA. 2021;118.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 21]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
59.  Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care. 2001;24:956-957.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 49]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
60.  Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, Diamanti-Kandarakis E, Kaltsas G, Kalofoutis A. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008;28:314-321.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 84]  [Cited by in F6Publishing: 88]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
61.  Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2015;144:171-185.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 195]  [Cited by in F6Publishing: 232]  [Article Influence: 25.8]  [Reference Citation Analysis (0)]
62.  Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Med Hypotheses. 2020;143:110111.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 31]  [Article Influence: 7.8]  [Reference Citation Analysis (0)]
63.  George TP, Joy SS, Rafiullah M, Siddiqui K. Cytokines Involved in COVID-19 Patients with Diabetes: A Systematic Review. Curr Diabetes Rev. 2023;19:18-28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Reference Citation Analysis (0)]
64.  Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16:377-390.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 218]  [Cited by in F6Publishing: 537]  [Article Influence: 134.3]  [Reference Citation Analysis (0)]
65.  Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6145]  [Cited by in F6Publishing: 5933]  [Article Influence: 258.0]  [Reference Citation Analysis (0)]
66.  Robertson CC, Rich SS. Genetics of type 1 diabetes. Curr Opin Genet Dev. 2018;50:7-16.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 45]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
67.  Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS; Type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703-707.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1270]  [Cited by in F6Publishing: 1289]  [Article Influence: 85.9]  [Reference Citation Analysis (0)]
68.  Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2:a007732.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 169]  [Cited by in F6Publishing: 185]  [Article Influence: 16.8]  [Reference Citation Analysis (0)]
69.  Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, Farber E, Bonnie JK, Szpak M, Schofield E, Achuthan P, Guo H, Fortune MD, Stevens H, Walker NM, Ward LD, Kundaje A, Kellis M, Daly MJ, Barrett JC, Cooper JD, Deloukas P; Type 1 Diabetes Genetics Consortium, Todd JA, Wallace C, Concannon P, Rich SS. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47:381-386.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 455]  [Cited by in F6Publishing: 461]  [Article Influence: 51.2]  [Reference Citation Analysis (0)]
70.  Ge Y, Onengut-Gumuscu S, Quinlan AR, Mackey AJ, Wright JA, Buckner JH, Habib T, Rich SS, Concannon P. Targeted Deep Sequencing in Multiple-Affected Sibships of European Ancestry Identifies Rare Deleterious Variants in PTPN22 That Confer Risk for Type 1 Diabetes. Diabetes. 2016;65:794-802.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 19]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
71.  Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, Gan W, Kitajima H, Taliun D, Rayner NW, Guo X, Lu Y, Li M, Jensen RA, Hu Y, Huo S, Lohman KK, Zhang W, Cook JP, Prins BP, Flannick J, Grarup N, Trubetskoy VV, Kravic J, Kim YJ, Rybin DV, Yaghootkar H, Müller-Nurasyid M, Meidtner K, Li-Gao R, Varga TV, Marten J, Li J, Smith AV, An P, Ligthart S, Gustafsson S, Malerba G, Demirkan A, Tajes JF, Steinthorsdottir V, Wuttke M, Lecoeur C, Preuss M, Bielak LF, Graff M, Highland HM, Justice AE, Liu DJ, Marouli E, Peloso GM, Warren HR; ExomeBP Consortium;  MAGIC Consortium;  GIANT Consortium, Afaq S, Afzal S, Ahlqvist E, Almgren P, Amin N, Bang LB, Bertoni AG, Bombieri C, Bork-Jensen J, Brandslund I, Brody JA, Burtt NP, Canouil M, Chen YI, Cho YS, Christensen C, Eastwood SV, Eckardt KU, Fischer K, Gambaro G, Giedraitis V, Grove ML, de Haan HG, Hackinger S, Hai Y, Han S, Tybjærg-Hansen A, Hivert MF, Isomaa B, Jäger S, Jørgensen ME, Jørgensen T, Käräjämäki A, Kim BJ, Kim SS, Koistinen HA, Kovacs P, Kriebel J, Kronenberg F, Läll K, Lange LA, Lee JJ, Lehne B, Li H, Lin KH, Linneberg A, Liu CT, Liu J, Loh M, Mägi R, Mamakou V, McKean-Cowdin R, Nadkarni G, Neville M, Nielsen SF, Ntalla I, Peyser PA, Rathmann W, Rice K, Rich SS, Rode L, Rolandsson O, Schönherr S, Selvin E, Small KS, Stančáková A, Surendran P, Taylor KD, Teslovich TM, Thorand B, Thorleifsson G, Tin A, Tönjes A, Varbo A, Witte DR, Wood AR, Yajnik P, Yao J, Yengo L, Young R, Amouyel P, Boeing H, Boerwinkle E, Bottinger EP, Chowdhury R, Collins FS, Dedoussis G, Dehghan A, Deloukas P, Ferrario MM, Ferrières J, Florez JC, Frossard P, Gudnason V, Harris TB, Heckbert SR, Howson JMM, Ingelsson M, Kathiresan S, Kee F, Kuusisto J, Langenberg C, Launer LJ, Lindgren CM, Männistö S, Meitinger T, Melander O, Mohlke KL, Moitry M, Morris AD, Murray AD, de Mutsert R, Orho-Melander M, Owen KR, Perola M, Peters A, Province MA, Rasheed A, Ridker PM, Rivadineira F, Rosendaal FR, Rosengren AH, Salomaa V, Sheu WH, Sladek R, Smith BH, Strauch K, Uitterlinden AG, Varma R, Willer CJ, Blüher M, Butterworth AS, Chambers JC, Chasman DI, Danesh J, van Duijn C, Dupuis J, Franco OH, Franks PW, Froguel P, Grallert H, Groop L, Han BG, Hansen T, Hattersley AT, Hayward C, Ingelsson E, Kardia SLR, Karpe F, Kooner JS, Köttgen A, Kuulasmaa K, Laakso M, Lin X, Lind L, Liu Y, Loos RJF, Marchini J, Metspalu A, Mook-Kanamori D, Nordestgaard BG, Palmer CNA, Pankow JS, Pedersen O, Psaty BM, Rauramaa R, Sattar N, Schulze MB, Soranzo N, Spector TD, Stefansson K, Stumvoll M, Thorsteinsdottir U, Tuomi T, Tuomilehto J, Wareham NJ, Wilson JG, Zeggini E, Scott RA, Barroso I, Frayling TM, Goodarzi MO, Meigs JB, Boehnke M, Saleheen D, Morris AP, Rotter JI, McCarthy MI. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet. 2018;50:559-571.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 330]  [Cited by in F6Publishing: 274]  [Article Influence: 45.7]  [Reference Citation Analysis (0)]
72.  Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878-1884.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 202]  [Cited by in F6Publishing: 185]  [Article Influence: 14.2]  [Reference Citation Analysis (0)]
73.  Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, Pezzolesi MG, McKeigue PM, Hiraki LT, Qiu C, Nair V, Di Liao C, Cao JJ, Valo E, Onengut-Gumuscu S, Smiles AM, McGurnaghan SJ, Haukka JK, Harjutsalo V, Brennan EP, van Zuydam N, Ahlqvist E, Doyle R, Ahluwalia TS, Lajer M, Hughes MF, Park J, Skupien J, Spiliopoulou A, Liu A, Menon R, Boustany-Kari CM, Kang HM, Nelson RG, Klein R, Klein BE, Lee KE, Gao X, Mauer M, Maestroni S, Caramori ML, de Boer IH, Miller RG, Guo J, Boright AP, Tregouet D, Gyorgy B, Snell-Bergeon JK, Maahs DM, Bull SB, Canty AJ, Palmer CNA, Stechemesser L, Paulweber B, Weitgasser R, Sokolovska J, Rovīte V, Pīrāgs V, Prakapiene E, Radzeviciene L, Verkauskiene R, Panduru NM, Groop LC, McCarthy MI, Gu HF, Möllsten A, Falhammar H, Brismar K, Martin F, Rossing P, Costacou T, Zerbini G, Marre M, Hadjadj S, McKnight AJ, Forsblom C, McKay G, Godson C, Maxwell AP, Kretzler M, Susztak K, Colhoun HM, Krolewski A, Paterson AD, Groop PH, Rich SS, Hirschhorn JN, Florez JC; SUMMIT Consortium, DCCT/EDIC Research Group, GENIE Consortium. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol. 2019;30:2000-2016.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 80]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
74.  Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C, Brusco A, Bosio M, Massella L, Lavoratti G, Roccatello D, Frascá G, Mazzucco G, Muda AO, Conti M, Fasciolo F, Arrondel C, Heidet L, Renieri A, De Marchi M. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. 2002;61:1947-1956.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 158]  [Cited by in F6Publishing: 141]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
75.  Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46:1829-1839.  [PubMed]  [DOI]  [Cited in This Article: ]
76.  Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, Hewitt AW, Sharma S, Daniell M, Essex RW, Chang JH, Klebe S, Lake SR, Pal B, Jenkins A, Govindarjan G, Sundaresan P, Lamoureux EL, Ramasamy K, Pefkianaki M, Hykin PG, Petrovsky N, Brown MA, Gillies MC, Craig JE. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia. 2015;58:2288-2297.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 43]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
77.  Meng W, Deshmukh HA, van Zuydam NR, Liu Y, Donnelly LA, Zhou K; Wellcome Trust Case Control Consortium 2 (WTCCC2);  Surrogate Markers for Micro- and Macro-Vascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) Study Group, Morris AD, Colhoun HM, Palmer CN, Smith BH. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. Eur J Pain. 2015;19:392-399.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 57]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
78.  Meng W, Deshmukh HA, Donnelly LA; Wellcome Trust Case Control Consortium 2 (WTCCC2);  Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) study group, Torrance N, Colhoun HM, Palmer CN, Smith BH. A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) With Diabetic Neuropathic Pain. EBioMedicine. 2015;2:1386-1393.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 55]  [Cited by in F6Publishing: 47]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
79.  Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, Meyer CG. Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine. 2021;72:103629.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 107]  [Cited by in F6Publishing: 99]  [Article Influence: 33.0]  [Reference Citation Analysis (0)]
80.  Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA. 2020;96:194-196.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 103]  [Cited by in F6Publishing: 127]  [Article Influence: 31.8]  [Reference Citation Analysis (0)]
81.  Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, Rogliani P, Leonardis F, Campana A, Carsetti R, Andreoni M, Bernardini S, Novelli G, Locatelli F. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. HLA. 2020;96:610-614.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 99]  [Article Influence: 24.8]  [Reference Citation Analysis (0)]
82.  Amoroso A, Magistroni P, Vespasiano F, Bella A, Bellino S, Puoti F, Alizzi S, Vaisitti T, Boros S, Grossi PA, Trapani S, Lombardini L, Pezzotti P, Deaglio S, Brusaferro S, Cardillo M; Italian Network of Regional Transplant Coordinating Centers. HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. Transplantation. 2021;105:193-200.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 68]  [Article Influence: 22.7]  [Reference Citation Analysis (0)]
83.  Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, Xian W, Qian X, Huang Y, Tang Q, Liu P, Chen R, Liu R, Li X, Tong X, Zhou X, Bai Y, Duan G, Zhang T, Xu X, Wang J, Yang H, Liu S, He Q, Jin X, Liu L. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6:83.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 148]  [Cited by in F6Publishing: 121]  [Article Influence: 30.3]  [Reference Citation Analysis (0)]
84.  Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M, Firinu D, Santus S, Lai A, Porcella R, Lai S, Rassu S, Scioscia R, Meloni F, Schirru D, Cordeddu W, Kowalik MA, Serra M, Ragatzu P, Carta MG, Del Giacco S, Restivo A, Orrù S, Palimodde A, Perra R, Orrù G, Conti M, Balestrieri C, Serra G, Onali S, Marongiu F, Perra A, Chessa L. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front Immunol. 2020;11:605688.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 80]  [Cited by in F6Publishing: 71]  [Article Influence: 17.8]  [Reference Citation Analysis (0)]
85.  Strafella C, Caputo V, Termine A, Barati S, Caltagirone C, Giardina E, Cascella R. Investigation of Genetic Variations of IL6 and IL6R as Potential Prognostic and Pharmacogenetics Biomarkers: Implications for COVID-19 and Neuroinflammatory Disorders. Life (Basel). 2020;10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 20]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
86.  Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians;  COVID Clinicians;  Imagine COVID Group;  French COVID Cohort Study Group;  CoV-Contact Cohort;  Amsterdam UMC Covid-19 Biobank;  COVID Human Genetic Effort;  NIAID-USUHS/TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner JD, Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli MJ, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton RP, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1558]  [Cited by in F6Publishing: 1445]  [Article Influence: 361.3]  [Reference Citation Analysis (0)]
87.  Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, Paciosi F, Schiaroli E, Baldassarri M, Fava F, Palmieri M, Ludovisi S, Castelli F, Quiros-Roldan E, Vaghi M, Rusconi S, Siano M, Bandini M, Spiga O, Capitani K, Furini S, Mari F; GEN-COVID Multicenter Study, Renieri A, Mondelli MU, Frullanti E. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. Elife. 2021;10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 118]  [Article Influence: 39.3]  [Reference Citation Analysis (0)]
88.  Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11946]  [Cited by in F6Publishing: 13059]  [Article Influence: 3264.8]  [Reference Citation Analysis (0)]
89.  Monticelli M, Hay Mele B, Benetti E, Fallerini C, Baldassarri M, Furini S, Frullanti E, Mari F, Andreotti G, Cubellis MV, Renieri A; Gen-Covid Multicenter Study. Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. Genes (Basel). 2021;12.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 24]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
90.  Martínez-Gómez LE, Herrera-López B, Martinez-Armenta C, Ortega-Peña S, Camacho-Rea MDC, Suarez-Ahedo C, Vázquez-Cárdenas P, Vargas-Alarcón G, Rojas-Velasco G, Fragoso JM, Vidal-Vázquez P, Ramírez-Hinojosa JP, Rodríguez-Sánchez Y, Barrón-Díaz D, Moreno ML, Martínez-Ruiz FJ, Zayago-Angeles DM, Mata-Miranda MM, Vázquez-Zapién GJ, Martínez-Cuazitl A, Barajas-Galicia E, Bustamante-Silva L, Zazueta-Arroyo D, Rodríguez-Pérez JM, Hernández-González O, Coronado-Zarco R, Lucas-Tenorio V, Franco-Cendejas R, López-Jácome LE, Vázquez-Juárez RC, Magaña JJ, Cruz-Ramos M, Granados J, Hernández-Doño S, Delgado-Saldivar D, Ramos-Tavera L, Coronado-Zarco I, Guajardo-Salinas G, Muñoz-Valle JF, Pineda C, Martínez-Nava GA, López-Reyes A. ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men. Front Immunol. 2022;13:812940.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 22]  [Article Influence: 11.0]  [Reference Citation Analysis (0)]
91.  Vadgama N, Kreymerman A, Campbell J, Shamardina O, Brugger C;  Research Consortium GE; Deaconescu AM, Lee RT, Penkett CJ, Gifford CA, Mercola M, Nasir J, Karakikes I. SARS-CoV-2 Susceptibility and ACE2 Gene Variations Within Diverse Ethnic Backgrounds. Front Genet. 2022;13:888025.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
92.  Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F, Kässens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A, Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A, Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julià A, Pesenti A, Voza A, Jiménez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C, Cea C, Solier A, Pestaña D, Muñiz-Diaz E, Sandoval E, Paraboschi EM, Navas E, García Sánchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Blasi F, Téllez L, Blanco-Grau A, Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara H, ElAbd H, My I, Galván-Femenia I, Martín J, Erdmann J, Ferrusquía-Acosta J, Garcia-Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro L, Scudeller L, Mesonero F, Roade L, Rühlemann MC, Schaefer M, Carrabba M, Riveiro-Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M, D'Angiò M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, Ciccarelli M, Rodríguez-Gandía M, Bocciolone M, Miozzo M, Montano N, Braun N, Sacchi N, Martínez N, Özer O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P, Rodrigues PM, Blandino Ortiz A, de Cid R, Ferrer R, Gualtierotti R, Nieto R, Goerg S, Badalamenti S, Marsal S, Matullo G, Pelusi S, Juzenas S, Aliberti S, Monzani V, Moreno V, Wesse T, Lenz TL, Pumarola T, Rimoldi V, Bosari S, Albrecht W, Peter W, Romero-Gómez M, D'Amato M, Duga S, Banales JM, Hov JR, Folseraas T, Valenti L, Franke A, Karlsen TH. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383:1522-1534.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1362]  [Cited by in F6Publishing: 1208]  [Article Influence: 302.0]  [Reference Citation Analysis (0)]
93.  Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, Furniss J, Richmond A, Gountouna E, Wrobel N, Harrison D, Wang B, Wu Y, Meynert A, Griffiths F, Oosthuyzen W, Kousathanas A, Moutsianas L, Yang Z, Zhai R, Zheng C, Grimes G, Beale R, Millar J, Shih B, Keating S, Zechner M, Haley C, Porteous DJ, Hayward C, Yang J, Knight J, Summers C, Shankar-Hari M, Klenerman P, Turtle L, Ho A, Moore SC, Hinds C, Horby P, Nichol A, Maslove D, Ling L, McAuley D, Montgomery H, Walsh T, Pereira AC, Renieri A; GenOMICC Investigators;  ISARIC4C Investigators;  COVID-19 Human Genetics Initiative;  23andMe Investigators;  BRACOVID Investigators;  Gen-COVID Investigators, Shen X, Ponting CP, Fawkes A, Tenesa A, Caulfield M, Scott R, Rowan K, Murphy L, Openshaw PJM, Semple MG, Law A, Vitart V, Wilson JF, Baillie JK. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92-98.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 869]  [Cited by in F6Publishing: 785]  [Article Influence: 261.7]  [Reference Citation Analysis (0)]
94.  COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472-477.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 386]  [Cited by in F6Publishing: 390]  [Article Influence: 130.0]  [Reference Citation Analysis (0)]
95.  Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D. APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020;75:2231-2232.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 174]  [Cited by in F6Publishing: 237]  [Article Influence: 59.3]  [Reference Citation Analysis (0)]
96.  Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1827]  [Cited by in F6Publishing: 2369]  [Article Influence: 789.7]  [Reference Citation Analysis (0)]
97.  SeyedAlinaghi S, Afsahi AM, MohsseniPour M, Behnezhad F, Salehi MA, Barzegary A, Mirzapour P, Mehraeen E, Dadras O. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch Acad Emerg Med. 2021;9:e14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 15]  [Reference Citation Analysis (0)]
98.  Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. Nat Med. 2021;27:626-631.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 731]  [Cited by in F6Publishing: 1224]  [Article Influence: 408.0]  [Reference Citation Analysis (0)]
99.  Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603-605.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2398]  [Cited by in F6Publishing: 2481]  [Article Influence: 620.3]  [Reference Citation Analysis (0)]
100.  Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021;174:576-578.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 329]  [Cited by in F6Publishing: 352]  [Article Influence: 117.3]  [Reference Citation Analysis (0)]
101.  Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR; ARC Study Group. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396-398.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 516]  [Cited by in F6Publishing: 480]  [Article Influence: 160.0]  [Reference Citation Analysis (0)]
102.  Martin-Villares C, Perez Molina-Ramirez C, Bartolome-Benito M, Bernal-Sprekelsen M; COVID ORL ESP Collaborative Group (*). Outcome of 1890 tracheostomies for critical COVID-19 patients: a national cohort study in Spain. Eur Arch Otorhinolaryngol. 2021;278:1605-1612.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 58]  [Article Influence: 14.5]  [Reference Citation Analysis (0)]
103.  Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM, Mao HL, Zhou XM, Luo H, Gao YF, Xu AG. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 480]  [Cited by in F6Publishing: 519]  [Article Influence: 129.8]  [Reference Citation Analysis (0)]
104.  Salem AM, Al Khathlan N, Alharbi AF, Alghamdi T, AlDuilej S, Alghamdi M, Alfudhaili M, Alsunni A, Yar T, Latif R, Rafique N, Al Asoom L, Sabit H. The Long-Term Impact of COVID-19 Pneumonia on the Pulmonary Function of Survivors. Int J Gen Med. 2021;14:3271-3280.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 13]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
105.  Raj SR, Arnold AC, Barboi A, Claydon VE, Limberg JK, Lucci VM, Numan M, Peltier A, Snapper H, Vernino S; American Autonomic Society. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021;31:365-368.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 115]  [Article Influence: 38.3]  [Reference Citation Analysis (0)]
106.  Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-1098.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1669]  [Cited by in F6Publishing: 1931]  [Article Influence: 482.8]  [Reference Citation Analysis (0)]
107.  Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-150.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1017]  [Cited by in F6Publishing: 1132]  [Article Influence: 283.0]  [Reference Citation Analysis (0)]
108.  Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 108]  [Cited by in F6Publishing: 102]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
109.  Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, Andreoli L, Franceschini F. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021;46:100745.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 107]  [Article Influence: 26.8]  [Reference Citation Analysis (0)]
110.  Inspiration Investigators, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Dobesh PP, Stone GW, Lip GYH, Krumholz HM, Goldhaber SZ, Bikdeli B. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325:1620-1630.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 387]  [Cited by in F6Publishing: 424]  [Article Influence: 141.3]  [Reference Citation Analysis (0)]
111.  Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76:122-124.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 651]  [Cited by in F6Publishing: 731]  [Article Influence: 182.8]  [Reference Citation Analysis (0)]
112.  Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S, Leaf DE, Kuter DJ, Rosovsky RP. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136:489-500.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 740]  [Cited by in F6Publishing: 863]  [Article Influence: 215.8]  [Reference Citation Analysis (0)]
113.  Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-232.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2783]  [Cited by in F6Publishing: 2577]  [Article Influence: 859.0]  [Reference Citation Analysis (1)]
114.  Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, Localio AR, Demissie E, Hopkins RO, Angus DC. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med. 2012;185:1307-1315.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 371]  [Cited by in F6Publishing: 398]  [Article Influence: 33.2]  [Reference Citation Analysis (0)]
115.  Sachdeva M, Gianotti R, Shah M, Bradanini L, Tosi D, Veraldi S, Ziv M, Leshem E, Dodiuk-Gad RP. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci. 2020;98:75-81.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 179]  [Cited by in F6Publishing: 137]  [Article Influence: 34.3]  [Reference Citation Analysis (0)]
116.  Mirza FN, Malik AA, Omer SB, Sethi A. Dermatologic manifestations of COVID-19: a comprehensive systematic review. Int J Dermatol. 2021;60:418-450.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 19]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
117.  Killion L, Beatty PE, Salim A. Rare cutaneous manifestation of COVID-19. BMJ Case Rep. 2021;14.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 5]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
118.  Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol. 2020;21:627-639.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 87]  [Article Influence: 21.8]  [Reference Citation Analysis (0)]
119.  Nikolopoulou GB, Maltezou HC. COVID-19 in Children: Where do we Stand? Arch Med Res. 2022;53:1-8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 110]  [Article Influence: 55.0]  [Reference Citation Analysis (0)]
120.  Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, Roguski K, Wallace B, Prezzato E, Koumans EH, Lee EH, Geevarughese A, Lash MK, Reilly KH, Pulver WP, Thomas D, Feder KA, Hsu KK, Plipat N, Richardson G, Reid H, Lim S, Schmitz A, Pierce T, Hrapcak S, Datta D, Morris SB, Clarke K, Belay E; California MIS-C Response Team. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1074-1080.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 416]  [Cited by in F6Publishing: 505]  [Article Influence: 126.3]  [Reference Citation Analysis (0)]
121.  Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG; Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1074-1087.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 434]  [Cited by in F6Publishing: 526]  [Article Influence: 175.3]  [Reference Citation Analysis (0)]
122.  Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180:2019-2034.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 176]  [Cited by in F6Publishing: 221]  [Article Influence: 73.7]  [Reference Citation Analysis (0)]
123.  Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, Randolph AG, Newhams M, Thomas D, Magleby R, Hsu K, Burns M, Dufort E, Maxted A, Pietrowski M, Longenberger A, Bidol S, Henderson J, Sosa L, Edmundson A, Tobin-D'Angelo M, Edison L, Heidemann S, Singh AR, Giuliano JS Jr, Kleinman LC, Tarquinio KM, Walsh RF, Fitzgerald JC, Clouser KN, Gertz SJ, Carroll RW, Carroll CL, Hoots BE, Reed C, Dahlgren FS, Oster ME, Pierce TJ, Curns AT, Langley GE, Campbell AP; MIS-C Incidence Authorship Group, Balachandran N, Murray TS, Burkholder C, Brancard T, Lifshitz J, Leach D, Charpie I, Tice C, Coffin SE, Perella D, Jones K, Marohn KL, Yager PH, Fernandes ND, Flori HR, Koncicki ML, Walker KS, Di Pentima MC, Li S, Horwitz SM, Gaur S, Coffey DC, Harwayne-Gidansky I, Hymes SR, Thomas NJ, Ackerman KG, Cholette JM. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021;4:e2116420.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 179]  [Cited by in F6Publishing: 235]  [Article Influence: 78.3]  [Reference Citation Analysis (0)]
124.  Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM, Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG; Overcoming COVID-19 Investigators;  CDC COVID-19 Response Team. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383:334-346.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1587]  [Cited by in F6Publishing: 1701]  [Article Influence: 425.3]  [Reference Citation Analysis (0)]
125.  Singh AK, Khunti K. COVID-19 and Diabetes. Annu Rev Med. 2022;73:129-147.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 35]  [Article Influence: 11.7]  [Reference Citation Analysis (0)]
126.  Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021;11:21.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 26]  [Article Influence: 8.7]  [Reference Citation Analysis (0)]
127.  Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC, Renard E. New-Onset Diabetes in Covid-19. N Engl J Med. 2020;383:789-790.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 487]  [Cited by in F6Publishing: 498]  [Article Influence: 124.5]  [Reference Citation Analysis (0)]
128.  Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, Mohan S. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney Int Rep. 2020;5:1149-1160.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 136]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
129.  Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219-227.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1054]  [Cited by in F6Publishing: 1193]  [Article Influence: 298.3]  [Reference Citation Analysis (0)]
130.  Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. 2020;16:565-567.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 95]  [Article Influence: 23.8]  [Reference Citation Analysis (0)]
131.  Jhaveri KD, Meir LR, Flores Chang BS, Parikh R, Wanchoo R, Barilla-LaBarca ML, Bijol V, Hajizadeh N. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020;98:509-512.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 93]  [Cited by in F6Publishing: 97]  [Article Influence: 24.3]  [Reference Citation Analysis (0)]
132.  Peleg Y, Kudose S, D'Agati V, Siddall E, Ahmad S, Nickolas T, Kisselev S, Gharavi A, Canetta P. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020;5:940-945.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 137]  [Cited by in F6Publishing: 144]  [Article Influence: 36.0]  [Reference Citation Analysis (0)]
133.  Kudose S, Batal I, Santoriello D, Xu K, Barasch J, Peleg Y, Canetta P, Ratner LE, Marasa M, Gharavi AG, Stokes MB, Markowitz GS, D'Agati VD. Kidney Biopsy Findings in Patients with COVID-19. J Am Soc Nephrol. 2020;31:1959-1968.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 213]  [Cited by in F6Publishing: 264]  [Article Influence: 66.0]  [Reference Citation Analysis (0)]
134.  Sharma P, Uppal NN, Wanchoo R, Shah HH, Yang Y, Parikh R, Khanin Y, Madireddy V, Larsen CP, Jhaveri KD, Bijol V; Northwell Nephrology COVID-19 Research Consortium. COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. J Am Soc Nephrol. 2020;31:1948-1958.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 251]  [Cited by in F6Publishing: 246]  [Article Influence: 61.5]  [Reference Citation Analysis (0)]
135.  Golmai P, Larsen CP, DeVita MV, Wahl SJ, Weins A, Rennke HG, Bijol V, Rosenstock JL. Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19. J Am Soc Nephrol. 2020;31:1944-1947.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 116]  [Article Influence: 29.0]  [Reference Citation Analysis (0)]
136.  Santoriello D, Khairallah P, Bomback AS, Xu K, Kudose S, Batal I, Barasch J, Radhakrishnan J, D'Agati V, Markowitz G. Postmortem Kidney Pathology Findings in Patients with COVID-19. J Am Soc Nephrol. 2020;31:2158-2167.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 176]  [Cited by in F6Publishing: 203]  [Article Influence: 50.8]  [Reference Citation Analysis (0)]
137.  Ali F, Elserafy M, Alkordi MH, Amin M. ACE2 coding variants in different populations and their potential impact on SARS-CoV-2 binding affinity. Biochem Biophys Rep. 2020;24:100798.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 24]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
138.  Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. Mol Genet Genomic Med. 2021;9:e1672.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 8]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
139.  Mohebbi A, Askari FS, Ebrahimi M, Zakeri M, Yasaghi M, Bagheri H, Javid N. Susceptibility of the Iranian population to severe acute respiratory syndrome coronavirus 2 infection based on variants of angiotensin I converting enzyme 2. Future Virol. 2020;507-514.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
140.  Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, Chen C, Jiang YP, Fellouse FA, Sathirapongsasuti JF, Albers PK, Deepak T, Saberianfar R, Ratan A, Washburn G, Mis M, Santhosh D, Somasekar S, Hiranjith GH, Vargas D, Mohan S, Phalke S, Kuriakose B, Antony A, Ustav M Jr, Schuster SC, Sidhu S, Junutula JR, Jura N, Seshagiri S. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun Biol. 2021;4:475.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 100]  [Cited by in F6Publishing: 99]  [Article Influence: 33.0]  [Reference Citation Analysis (0)]
141.  Han P, Li L, Liu S, Wang Q, Zhang D, Xu Z, Han P, Li X, Peng Q, Su C, Huang B, Li D, Zhang R, Tian M, Fu L, Gao Y, Zhao X, Liu K, Qi J, Gao GF, Wang P. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell. 2022;185:630-640.e10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 302]  [Cited by in F6Publishing: 283]  [Article Influence: 141.5]  [Reference Citation Analysis (0)]
142.  Tahsin A, Ahmed R, Bhattacharjee P, Adiba M, Al Saba A, Yasmin T, Chakraborty S, Hasan AKMM, Nabi AHMN. Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages. Comput Biol Med. 2022;148:105903.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
143.  Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021;10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 226]  [Cited by in F6Publishing: 213]  [Article Influence: 71.0]  [Reference Citation Analysis (0)]
144.  Möhlendick B, Schönfelder K, Breuckmann K, Elsner C, Babel N, Balfanz P, Dahl E, Dreher M, Fistera D, Herbstreit F, Hölzer B, Koch M, Kohnle M, Marx N, Risse J, Schmidt K, Skrzypczyk S, Sutharsan S, Taube C, Westhoff TH, Jöckel KH, Dittmer U, Siffert W, Kribben A. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genomics. 2021;31:165-171.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 62]  [Article Influence: 20.7]  [Reference Citation Analysis (0)]
145.  Celik I, Yadav R, Duzgun Z, Albogami S, El-Shehawi AM, Fatimawali, Idroes R, Tallei TE, Emran TB. Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. Biology (Basel). 2021;10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 25]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
146.  Pan Y, Wang T, Li Y, Guan T, Lai Y, Shen Y, Zeyaweiding A, Maimaiti T, Li F, Zhao H, Liu C. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17:241.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 52]  [Article Influence: 8.7]  [Reference Citation Analysis (0)]
147.  Zhang Q, Cong M, Wang N, Li X, Zhang H, Zhang K, Jin M, Wu N, Qiu C, Li J. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study. Medicine (Baltimore). 2018;97:e12917.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 61]  [Article Influence: 10.2]  [Reference Citation Analysis (0)]
148.  Lieb W, Graf J, Götz A, König IR, Mayer B, Fischer M, Stritzke J, Hengstenberg C, Holmer SR, Döring A, Löwel H, Schunkert H, Erdmann J. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med (Berl). 2006;84:88-96.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 83]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
149.  Karakaş Çelik S, Çakmak Genç G, Pişkin N, Açikgöz B, Altinsoy B, Kurucu İşsiz B, Dursun A. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study. J Med Virol. 2021;93:5947-5952.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 52]  [Article Influence: 17.3]  [Reference Citation Analysis (0)]
150.  Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL, D'Apice MR, Rogliani P, Zaffina S, Leonardis F, Campana A, Raponi M, Andreoni M, Grelli S, Novelli G. Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Hum Genomics. 2020;14:29.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 51]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
151.  Gómez J, Albaiceta GM, García-Clemente M, López-Larrea C, Amado-Rodríguez L, Lopez-Alonso I, Hermida T, Enriquez AI, Herrero P, Melón S, Alvarez-Argüelles ME, Boga JA, Rojo-Alba S, Cuesta-Llavona E, Alvarez V, Lorca R, Coto E. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762:145102.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 87]  [Cited by in F6Publishing: 131]  [Article Influence: 32.8]  [Reference Citation Analysis (0)]
152.  Sienko J, Marczak I, Kotowski M, Bogacz A, Tejchman K, Sienko M, Kotfis K. Association of ACE2 Gene Variants with the Severity of COVID-19 Disease-A Prospective Observational Study. Int J Environ Res Public Health. 2022;19.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 6]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
153.  Cafiero C, Rosapepe F, Palmirotta R, Re A, Ottaiano MP, Benincasa G, Perone R, Varriale E, D'Amato G, Cacciamani A, Micera A, Pisconti S. Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. Pharmgenomics Pers Med. 2021;14:621-629.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 28]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
154.  Hamet P, Pausova Z, Attaoua R, Hishmih C, Haloui M, Shin J, Paus T, Abrahamowicz M, Gaudet D, Santucci L, Kotchen TA, Cowley AW, Hussin J, Tremblay J. SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. Am J Hypertens. 2021;34:367-376.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 25]  [Article Influence: 8.3]  [Reference Citation Analysis (0)]
155.  Wu KCH, He Q, Bennett AN, Li J, Chan KHK. Shared genetic mechanism between type 2 diabetes and COVID-19 using pathway-based association analysis. Front Genet. 2022;13:1063519.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]